Literature DB >> 10824647

Interferons, serotonin and neurotoxicity.

D B Menkes1, J A MacDonald.   

Abstract

BACKGROUND: Interferons are a class of cytokines profoundly affecting immune function. Several interferons are now synthesized and used clinically, notably for viral diseases and cancer. In addition to their desired immune effects, interferons cause a number of toxicities, including prominent effects on the nervous system.
METHODS: This literature review focused on the incidence of depression associated with interferon treatment. Possible neurochemical mechanisms and remedial strategies were also considered.
RESULTS: Interferon treatment, particularly with the alpha subtype, is unquestionably linked with depression, but the strength of association is uncertain because of erratic ascertainment and pretreatment co-morbidity. A likely pathogenic mechanism has been described, involving interferon suppression of serotonin synthesis. Controlled treatment trials of interferon-induced depression are not yet available.
CONCLUSIONS: Neurotoxicity substantially limits the use of interferons. At least some of the risk of depression appears to derive from their anti-serotonergic effects, consistent with the large body of evidence pointing to a general link between serotonin and affective illness. Vigilant detection and aggressive treatment of depression is necessary to optimize interferon treatment of many patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10824647     DOI: 10.1017/s0033291799001774

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  10 in total

1.  Assessment of depression in a rodent model of spinal cord injury.

Authors:  Kelsey Luedtke; Sioui Maldonado Bouchard; Sarah A Woller; Mary Katherine Funk; Miriam Aceves; Michelle A Hook
Journal:  J Neurotrauma       Date:  2014-05-08       Impact factor: 5.269

2.  The detection and treatment of depression in the physically ill.

Authors:  David Goldberg
Journal:  World Psychiatry       Date:  2010-02       Impact factor: 49.548

Review 3.  An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1).

Authors:  Cyril X George; Lijo John; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2014-06       Impact factor: 2.607

Review 4.  Editing of neurotransmitter receptor and ion channel RNAs in the nervous system.

Authors:  Jennifer L Hood; Ronald B Emeson
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

5.  A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C.

Authors:  J M Loftis; J M Wall; E Linardatos; S Benvenga; P Hauser
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

Review 6.  Neuropsychiatric side effects of interferon-alfa therapy.

Authors:  Arthur R Van Gool; Wim H J Kruit; Frederike K Engels; Gerrit Stoter; Marjolein Bannink; Alexander M M Eggermont
Journal:  Pharm World Sci       Date:  2003-02

7.  The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Sarah Canning; Mitch Waterman; Nic Orsi; Julie Ayres; Nigel Simpson; Louise Dye
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

8.  Toward an anti-inflammatory strategy for depression.

Authors:  Shawn Hayley
Journal:  Front Behav Neurosci       Date:  2011-04-13       Impact factor: 3.558

9.  Completion of chronic hepatitis C virus treatment in interferon-induced major depressive disorder with psychotic features.

Authors:  Susie H Park
Journal:  Psychiatry Investig       Date:  2011-11-14       Impact factor: 2.505

10.  Gluten-free diet may alleviate depressive and behavioural symptoms in adolescents with coeliac disease: a prospective follow-up case-series study.

Authors:  Päivi A Pynnönen; Erkki T Isometsä; Matti A Verkasalo; Seppo A Kähkönen; Ilkka Sipilä; Erkki Savilahti; Veikko A Aalberg
Journal:  BMC Psychiatry       Date:  2005-03-17       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.